The therapy response observed in our patient, together with the tumor’s molecular profile characteristic of the POLD1 signature, support our hypothesis that discordant AA substitution in the DEDD motif would lead to exonuclease dysfunction resulting in DNA proofreading defect and an increased level of neoantigen production, ultimately promoting anti-tumor immunity. This evidence concerns the gene POLD1 and neoplasm.